S NCBI	eotide F	Publ	Med	C PMC	National Library of Medicine	OMIM	В
Search PubMed	for				Go Ge	ar 🖁	
About Entrez	Limit			story	Clipboard	Det	tails
Text Version	Display	Abstract	Show: 2	O 👺 Sor	t Se	nd to Te	ext
Entrez PubMed Overview Help FAQ Tutorial New/Noteworthy E-Utilities	Plat	ol Chem. 1987 Jul E full text article of www.jbc.org telet glycoprote chment to adh	ein IIb-IIIa-li	ike protei			lial d
PubMed Services Journals Database MeSH Database Single Citation Matcher Batch Citation Matcher Clinical Queries LinkOut Cubby Related Resources Order Documents NLM Gateway TOXNET Consumer Health Clinical Alerts ClinicalTrials.gov PubMed Central Privacy Policy	The matrimed HUV vitro coate vitro antibadhe mon Thes	adherence of hum ix proteins was exiated by the glycower cells adhered where the concern, fibrinoger and on to uncoated onectin, fibrinoger II a monoclonal amonoclonal amonoc	nan umbilical voxamined to determined to determined to determine the protein (GP) II well to glass slides. The HU in, and von Willen, and rear particular for the control of the	ein endothermine if ce b-IIIa com des that had rand facto VE cell attebrand facto In contrast, but was in o effect or but not all heir natura Ib-IIIa-like eins and to	ell attachment a plex on endoth d been coated variety but failed to a rachment and space or were greatly, HUVE cell attachment in cell attachment pha GP140, disably occurring e proteins medicate of the extracellul	and spread elial cells with fibroradhere to a preading of inhibited tachment to tronectin-int to the of trupted HU extracellula ate the add	ding to The nectical burson to recepther UVE ar many theres the neces that the neces the neces that the nece

Write to the Help Desk

NCBI | NLM | NIH

Department of Health & Human Services

Freedom of Information Act | Disclaimer


Show: 20 Sort

Aug 6 200:

Send to

Display

Abstract



PMID: 8424789 [PubMed - indexed for MEDLINE]

and on fibrinogen.


Silow. 20 1001	Display Abstract	Show:		Sort 👺	Send to. Tex	-
----------------	------------------	-------	--	--------	--------------	---

Write to the Help Desk NCBI | NLM | NIH Department of Health & Human Services

from known platelet-binding domains within the fibrinogen alpha- and gamn chains, although the GP IIb-IIIa complex did. These results show that the complexed form of full-length GP IIb and GP IIIa is required for binding to t synthetic peptides, but not necessarily for binding to immobilized fibringen GP IIb-IIIa can bind to immobilized fibringen by a distinct mechanism that appears to involve novel binding sites on each subunit of the GP IIb-IIIa com ANTICANCER DRUGS 1996 7:723-7







S NC	31	P	mpdn,	ed	of	Library Medicine N		
PubMed	Nucleotide	Protein	Genome	Structure	PMC	Taxonomy	OMIM	Вс
Search PubMe	d 💆	for		is the sentiment of the section of the section in the section of t	**************************************	Go Cle	ar	
		Limits	Preview/Index	History	/	Clipboard	Deta	ails
About Entrez								
	* Dis	play Absti	ract	Show: 20	Sort	Se Se	nd to Te	ext
Text Version								
Entrez PubMed	□1:	Br J Cancer	. 1998 Mar;77(6):956-64.			Related A	Article

Help | FAQ Tutorial New/Noteworthy E-Utilities

PubMed Services Journals Database MeSH Database Single Citation Matcher **Batch Citation Matcher** Clinical Queries LinkOut Cubby

Related Resources Order Documents **NLM Gateway** TOXNET Consumer Health Clinical Alerts ClinicalTrials.gov PubMed Central

Privacy Policy

ANAS /1997 94:663-8

CLIN CAPILER RES 12/1997 3:2187-90 Comment in:

Br J Cancer. 1999 Jan; 79(2):370-3.

Release of the angiogenic cytokine vascular endothelial growth f (VEGF) from platelets: significance for VEGF measurements arcancer biology.

Banks RE, Forbes MA, Kinsey SE, Stanley A, Ingham E, Walters C, Sell

ICRF Cancer Medicine Research Unit, St James's University Hospital, Leeds

Vascular endothelial growth factor (VEGE)-is-a-potent-angiogenic factor-with key role in several pathological processes, including tumour vascularization. preliminary observations indicated higher VEGF concentrations in serum sar than in matched plasma samples. We have now demonstrated that this differe due to the presence of VEGF within platelets and its release upon their active during coagulation. In eight healthy volunteers, serum VEGF concentrations ranged from 76 to 854 pg ml(-1) and were significantly higher (P < 0.01) tha matched citrated plasma VEGF concentrations, which ranged from < 9 to 42 (-1). Using platelet-rich plasma, mean (s.d.) platelet VEGF contents of 0.56 (pg of VEGF 10(-6) platelets were found. Immunocytochemistry demonstrate cytoplasmic presence of VEGF within megakaryocytes and other cell types v the bone marrow. From examination of the effects of blood sample processin circulating VEGF concentrations, it is apparent that for accurate measuremen citrated plasma processed within 1 h of venepuncture should be used. Serum completely unsuitable. The presence of VEGF within platelets has implication processes involving platelet and endothelial cell interactions. e.g. wound heal and in tumour metastasis, when platelets adhering to circulating tumour cells release VEGF at points of adhesion to endothelium, leading to hyperpermeat and extravasation of cells.

PMID: 9528841 [PubMed - indexed for MEDLINE]

EUR J CANCER 32A 2401 Display Abstract Send to Show: 20 Sort Text







Ρ	ub	M	e	d
•	uv	·IV	U	u

Nucleotide

Protein Genome Structure

PMC

Taxonomy Go Clear Bc

Search PubMed

for Limits

Preview/Index

History

Clipboard

Details

OMIM

About Entrez

Display

E.

Show: 20

Sort

Send to

Text

Text Version

1: Clin Cancer Res. 1997 Dec;3(12 Pt 1):2187-90. Entrez PubMed

Abstract

Related Article

Overview Help | FAQ Tutorial New/Noteworthy E-Utilities

Platelet: transporter of vascular endothelial growth factor.

Verheul HM, Hoekman K, Luykx-de Bakker S, Eekman CA, Folman CC Broxterman HJ, Pinedo HM.

Department of Medical Oncology, University Hospital "Vrije Universiteit," 1 MB Amsterdam, The Netherlands.

In animal models, growth of tumors and their metastases is dependent on facthat stimulate vessel formation (angiogenesis). Most clinical studies confirm importance of angiogenesis for cancer growth in patients. Recent studies on circulating angiogenic factors in patients have focused on serum vascular endothelial growth factor (VEGF) levels in a variety of cancer types. We me: serum VEGF concentrations and blood counts in 27 breast cancer patients du each of 6 cycles of chemotherapy with doxorubicin and cyclophosphamide supported by granulocyte macrophage colony-stimulating factor. Serum VEC concentrations highly correlated with platelet counts during chemotherapy (r P < 0.01). In particular, during the first treatment cycle, after an initial episoc thrombocytopenia, a strong platelet rebound coincided closely with a serum peak (r = 0.9; P < 0.01). In addition, plasma VEGF concentrations from 15 o cancer patients and 30 healthy volunteers were 5- to 8-fold lower than their corresponding serum VEGF concentrations (P < 0.001). Activation of platele increased the VEGF content 8-10 times. These findings demonstrate that VE released by platelets during serum preparation. In this study, we found evider VEGF transport by platelets, indicating that serum VEGF concentrations refl mainly platelet counts rather than tumor burden in cancer patients, as reporte earlier. Platelets, known to be important for wound healing, have also been reported to contribute to metastasis formation and tumor growth in animal m-Indeed, tumors can be regarded as never-healing wounds. Our data suggest the platelets may have a stimulating role on angiogenesis-dependent tumor grow through their function as transporters of VEGF.

PubMed Services

Journals Database MeSH Database Single Citation Matcher **Batch Citation Matcher** Clinical Queries LinkOut Cubby

Related Resources

Order Documents NLM Gateway TOXNET Consumer Health Clinical Alerts ClinicalTrials.gov PubMed Central

Privacy Policy

LANLET 1996 352:1775

PMID: 9815613 [PubMed - indexed for MEDLINE]

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=98156... 8/13/03

+ CLIN INVEST 96: 1815-12 1995